p#24-25 might be absent from the Nov. 30 set of dataSimply a question of timing!
We know this:
June 11, 2021:
- To date, Study II has enrolled and provided the primary study treatment for 20 patients (including three patients from Phase Ib study treated at the Therapeutic Dose) for a total of 23 patients.
August 30, 2021:
- The current interim analysis of the clinical data (with significant clinical data still pending and based on only 27 patients (24 + 3??)) demonstrates that Study II’s primary (33.3%) and tertiary objectives (1 Severe AE) demonstrate a strong initial efficacy, strong durable efficacy and a high safety profile. There is insufficient data to comment on the Study II secondary objective.
That means that p#24 was treated somewhere in August. Could be August 10, 14, 21, 22 ...
Lets assume, for the sake of discussion, that he made the cut in extremist on August 29, 2021. His 450-days would be Nov. 22, 2022. So 3 days ago. We have 5 days left to the Q32022 financials. So that would leave only 8 days from the 450-days for the urologist to commmunicate the data to the CRO, that would then communicate it to TLT! Consider also that there's a room of manoeuver of +-7 days for milestone exams. Fair to assume that TLT management did the necessary to have p#24 on time.
So chances that we have data on p#24 is possible, but it is also possible that we don't have them in time for the Q3-2022 data. That would give us a less precise lecture on the DR% @-450-days as our pool of patients would be missing p#24-25.
But that wouldn't be dramatic either. We would still have data on up to p#23. We would also be able to focus on the 7 "pending status" patients to see if they all turned TR, as oppose to NR, in regards to CR% @90-days.
Interesting times ahead.